CA2866896C - Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion - Google Patents

Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion Download PDF

Info

Publication number
CA2866896C
CA2866896C CA2866896A CA2866896A CA2866896C CA 2866896 C CA2866896 C CA 2866896C CA 2866896 A CA2866896 A CA 2866896A CA 2866896 A CA2866896 A CA 2866896A CA 2866896 C CA2866896 C CA 2866896C
Authority
CA
Canada
Prior art keywords
iron oxide
acrylamide
drug
biomaterial
microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2866896A
Other languages
English (en)
French (fr)
Other versions
CA2866896A1 (en
Inventor
Philippe Reb
Celine Chaix
Meriadeg THOMAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosphere Medical Inc
Original Assignee
Biosphere Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosphere Medical Inc filed Critical Biosphere Medical Inc
Publication of CA2866896A1 publication Critical patent/CA2866896A1/en
Application granted granted Critical
Publication of CA2866896C publication Critical patent/CA2866896C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
CA2866896A 2012-05-24 2013-05-23 Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion Active CA2866896C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651389P 2012-05-24 2012-05-24
US61/651,389 2012-05-24
PCT/US2013/042363 WO2013177364A1 (en) 2012-05-24 2013-05-23 Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion

Publications (2)

Publication Number Publication Date
CA2866896A1 CA2866896A1 (en) 2013-11-28
CA2866896C true CA2866896C (en) 2021-01-26

Family

ID=49621771

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2866896A Active CA2866896C (en) 2012-05-24 2013-05-23 Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion

Country Status (7)

Country Link
US (1) US10695440B2 (https=)
EP (2) EP2854869B1 (https=)
JP (1) JP6208749B2 (https=)
BR (1) BR112014029149A2 (https=)
CA (1) CA2866896C (https=)
ES (1) ES2655656T3 (https=)
WO (1) WO2013177364A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177364A1 (en) 2012-05-24 2013-11-28 Biosphere Medical, Inc. Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion
JP6641265B2 (ja) 2013-09-19 2020-02-05 マイクロベンション インコーポレイテッドＭｉｃｒｏｖｅｎｔｉｏｎ， Ｉｎｃ． ポリマーフィルム
EP3046952B1 (en) 2013-09-19 2021-05-12 Terumo Corporation Polymer particles
EP3065719A4 (en) 2013-11-08 2017-08-09 Terumo Corporation Polymer particles
WO2016154592A1 (en) 2015-03-26 2016-09-29 Microvention, Inc. Embiolic particles
EP4279139A3 (en) 2016-09-28 2024-01-24 Terumo Corporation Polymer particles

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509858A (https=) 1973-06-02 1975-01-31
JPS6056676B2 (ja) 1980-07-18 1985-12-11 日立造船株式会社 コンクリ−ト複合パネル
ATE130517T1 (de) 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
FR2676927B1 (fr) * 1991-05-29 1995-06-23 Ibf Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant.
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US6315709B1 (en) 1998-08-07 2001-11-13 Stereotaxis, Inc. Magnetic vascular defect treatment system
KR100872884B1 (ko) 2000-03-24 2008-12-10 바이오스피어 메디칼 인코포레이티드 능동 색전화용 미소구
FR2808026B1 (fr) * 2000-04-25 2002-06-14 Alexandre Laurent Biomateriau a base de polymere hydrophile presentant un signal specifique en imagerie par resonance magnetique et procede de preparation d'un tel biomateriau
JP2005053707A (ja) 2001-07-30 2005-03-03 Kankyo Device Kenkyusho:Kk 可視光応答性材料の製造方法
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US20040161466A1 (en) * 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
JP4909071B2 (ja) 2003-03-24 2012-04-04 プルーローメッド， インコーポレイテッド 逆感熱性ポリマーを使用する一時的な塞栓形成
WO2005044224A2 (en) 2003-05-02 2005-05-19 Case Western Reserve University Drug delivery system based on polymer nanoshells
EP2202250B1 (en) * 2004-08-19 2013-10-09 Covidien LP Water-swellable copolymers and articles and coating made therefrom
EP2229147A2 (en) * 2007-12-03 2010-09-22 The Johns Hopkins University Methods of synthesis and use of chemospheres
GB0807154D0 (en) * 2008-04-18 2008-05-21 Univ Aston Intervertebral disc
JP5792714B2 (ja) * 2009-05-28 2015-10-14 コーニング インコーポレイテッド 細胞培養のための膨潤性の合成マイクロキャリア
EP2451488A2 (en) * 2009-07-07 2012-05-16 Bartling, Sönke Multimodal visible polymer embolization material
WO2013177364A1 (en) 2012-05-24 2013-11-28 Biosphere Medical, Inc. Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion

Also Published As

Publication number Publication date
US20130315838A1 (en) 2013-11-28
US10695440B2 (en) 2020-06-30
EP3295961B1 (en) 2020-04-08
WO2013177364A1 (en) 2013-11-28
ES2655656T3 (es) 2018-02-21
JP2015517390A (ja) 2015-06-22
EP3295961A1 (en) 2018-03-21
EP2854869A1 (en) 2015-04-08
JP6208749B2 (ja) 2017-10-04
BR112014029149A2 (pt) 2017-06-27
EP2854869B1 (en) 2017-11-01
EP2854869A4 (en) 2015-12-30
CA2866896A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
CA2866896C (en) Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion
US11998563B2 (en) Polymeric treatment compositions
US5635215A (en) Microspheres useful for therapeutic vascular occlusions and injectable solutions containing the same
KR20150071025A (ko) 폴리머 치료 조성물
US12390530B2 (en) Stimuli responsive block copolymers
JP2022046815A (ja) 粒子を含むエマルジョン
TW201718016A (zh) 聚合物及微球體
WO2024206400A1 (en) Liquid embolic materials
EP4688015A1 (en) Liquid embolic materials
HK1262990A1 (zh) 包含颗粒的乳液

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180223

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401